The company said on Wednesday the sale was part of a pre-announced trading plan, adopted by Bourla on Aug. 19. Bourla sold 132,508 shares at $41.94 per share, according to a Securities and Exchange Commission filing late Tuesday. “The sale of these shares is part of Dr. Bourla’s personal financial planning and a pre-established (10b5-1) plan, which allows, under SEC rules, major shareholders and insiders of exchange-listed corporations to trade a predetermined number of shares at a predetermined time,” Pfizer said. …read more
Source:: Yahoo Finance
